Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors
ObjectiveThis article aims to analyze the safety and efficacy of Erdafitinib in the treatment of patients with advanced solid tumors harboring FGFR1–4 mutations.MethodsSearch for relevant articles in databases such as PubMed, Embase, The Cochrane Library, Web of Science, and CNKI, covering the perio...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1571434/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850043803097890816 |
|---|---|
| author | Jiyu Huang Zihan Wang Fei Zhao Adilai Aisa Shengkai Tian Siyuan Chen Lianyi Peng Xiaolu Yang Jianxin He Jianxin He Yue Yang |
| author_facet | Jiyu Huang Zihan Wang Fei Zhao Adilai Aisa Shengkai Tian Siyuan Chen Lianyi Peng Xiaolu Yang Jianxin He Jianxin He Yue Yang |
| author_sort | Jiyu Huang |
| collection | DOAJ |
| description | ObjectiveThis article aims to analyze the safety and efficacy of Erdafitinib in the treatment of patients with advanced solid tumors harboring FGFR1–4 mutations.MethodsSearch for relevant articles in databases such as PubMed, Embase, The Cochrane Library, Web of Science, and CNKI, covering the period from their establishment to October 25, 2024. Summarize the adverse drug reaction (AE) data, overall survival (OS), median progression-free survival (PFS), objective response rate (ORR), and other relevant data for patients with advanced solid tumors treated with Erdafitinib for FGFR1–4 mutations. Conduct a meta-analysis on the corresponding summarized data using the software Stata 18.0.ResultsThrough our search, we identified a total of 10 articles involving 1019 patients. In urothelial carcinoma, the most prevalent adverse reactions are hyperphosphatemia (78.5%), diarrhea (56.5%), and stomatitis (51.1%). The most frequently reported adverse reactions in other solid tumors are hyperphosphatemia (66.5%), dry mouth (48.5%), and diarrhea (44.9%). Patients with urothelial carcinoma treated with Erdafitinib exhibit higher median progression-free survival (PFS) and objective response rate (ORR) compared to those treated with other solid tumor therapies.ConclusionCurrent evidence indicates that Erdafitinib exhibits certain therapeutic efficacy in the treatment of advanced solid tumors harboring FGFR1–4 mutations, with the most pronounced therapeutic effect observed in urothelial carcinoma. The efficacy of Erdafitinib in treating other solid tumors requires further confirmation through larger-scale studies involving a broader range of FGFR1–4 mutant tumors. |
| format | Article |
| id | doaj-art-c63d5fd79a644bca9b874b0c961de3e1 |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-c63d5fd79a644bca9b874b0c961de3e12025-08-20T02:55:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-08-011510.3389/fonc.2025.15714341571434Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumorsJiyu Huang0Zihan Wang1Fei Zhao2Adilai Aisa3Shengkai Tian4Siyuan Chen5Lianyi Peng6Xiaolu Yang7Jianxin He8Jianxin He9Yue Yang10Medical College, Northwest University for Nationalities, Lanzhou, ChinaMedical College, Northwest University for Nationalities, Lanzhou, ChinaMedical College, Northwest University for Nationalities, Lanzhou, ChinaMedical College, Northwest University for Nationalities, Lanzhou, ChinaMedical College, Northwest University for Nationalities, Lanzhou, ChinaChina Medical University, Shenyang, Liaoning, ChinaMedical College, Northwest University for Nationalities, Lanzhou, ChinaMedical College, Northwest University for Nationalities, Lanzhou, ChinaGansu University of Chinese Medicine, Lanzhou, Gansu, ChinaKey Laboratory of Dunhuang Medicine and Transformation, Gansu University of Chinese Medicine, Lanzhou, Gansu, ChinaMedical College, Northwest University for Nationalities, Lanzhou, ChinaObjectiveThis article aims to analyze the safety and efficacy of Erdafitinib in the treatment of patients with advanced solid tumors harboring FGFR1–4 mutations.MethodsSearch for relevant articles in databases such as PubMed, Embase, The Cochrane Library, Web of Science, and CNKI, covering the period from their establishment to October 25, 2024. Summarize the adverse drug reaction (AE) data, overall survival (OS), median progression-free survival (PFS), objective response rate (ORR), and other relevant data for patients with advanced solid tumors treated with Erdafitinib for FGFR1–4 mutations. Conduct a meta-analysis on the corresponding summarized data using the software Stata 18.0.ResultsThrough our search, we identified a total of 10 articles involving 1019 patients. In urothelial carcinoma, the most prevalent adverse reactions are hyperphosphatemia (78.5%), diarrhea (56.5%), and stomatitis (51.1%). The most frequently reported adverse reactions in other solid tumors are hyperphosphatemia (66.5%), dry mouth (48.5%), and diarrhea (44.9%). Patients with urothelial carcinoma treated with Erdafitinib exhibit higher median progression-free survival (PFS) and objective response rate (ORR) compared to those treated with other solid tumor therapies.ConclusionCurrent evidence indicates that Erdafitinib exhibits certain therapeutic efficacy in the treatment of advanced solid tumors harboring FGFR1–4 mutations, with the most pronounced therapeutic effect observed in urothelial carcinoma. The efficacy of Erdafitinib in treating other solid tumors requires further confirmation through larger-scale studies involving a broader range of FGFR1–4 mutant tumors.https://www.frontiersin.org/articles/10.3389/fonc.2025.1571434/fullerdafitiniburothelial carcinomaFGFR1-4tumorsmeta-analysis |
| spellingShingle | Jiyu Huang Zihan Wang Fei Zhao Adilai Aisa Shengkai Tian Siyuan Chen Lianyi Peng Xiaolu Yang Jianxin He Jianxin He Yue Yang Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors Frontiers in Oncology erdafitinib urothelial carcinoma FGFR1-4 tumors meta-analysis |
| title | Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors |
| title_full | Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors |
| title_fullStr | Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors |
| title_full_unstemmed | Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors |
| title_short | Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors |
| title_sort | meta analysis on the safety and efficacy of erdafitinib in treating fgfr1 4 mutated solid tumors |
| topic | erdafitinib urothelial carcinoma FGFR1-4 tumors meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1571434/full |
| work_keys_str_mv | AT jiyuhuang metaanalysisonthesafetyandefficacyoferdafitinibintreatingfgfr14mutatedsolidtumors AT zihanwang metaanalysisonthesafetyandefficacyoferdafitinibintreatingfgfr14mutatedsolidtumors AT feizhao metaanalysisonthesafetyandefficacyoferdafitinibintreatingfgfr14mutatedsolidtumors AT adilaiaisa metaanalysisonthesafetyandefficacyoferdafitinibintreatingfgfr14mutatedsolidtumors AT shengkaitian metaanalysisonthesafetyandefficacyoferdafitinibintreatingfgfr14mutatedsolidtumors AT siyuanchen metaanalysisonthesafetyandefficacyoferdafitinibintreatingfgfr14mutatedsolidtumors AT lianyipeng metaanalysisonthesafetyandefficacyoferdafitinibintreatingfgfr14mutatedsolidtumors AT xiaoluyang metaanalysisonthesafetyandefficacyoferdafitinibintreatingfgfr14mutatedsolidtumors AT jianxinhe metaanalysisonthesafetyandefficacyoferdafitinibintreatingfgfr14mutatedsolidtumors AT jianxinhe metaanalysisonthesafetyandefficacyoferdafitinibintreatingfgfr14mutatedsolidtumors AT yueyang metaanalysisonthesafetyandefficacyoferdafitinibintreatingfgfr14mutatedsolidtumors |